We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
Read MoreHide Full Article
Key Takeaways
IBRX is expanding Anktiva beyond NMIBC into broader oncology indications to drive growth.
Studies include bladder cancer, NSCLC, pancreatic and other tumors using combo therapies.
Strong competition from Merck, Bristol Myers and Roche may challenge market penetration.
ImmunityBio’s (IBRX - Free Report) growth narrative is increasingly tied to the expansion potential of its sole marketed drug, Anktiva, beyond its initial approval in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). While the current label establishes a commercial foothold, the company is advancing multiple clinical programs aimed at extending the therapy’s use across broader oncology indications.
ImmunityBio is evaluating Anktiva in several clinical studies spanning solid tumors and hematologic malignancies as part of its broader Cancer BioShield platform strategy. Under this approach, the therapy acts as a backbone immunotherapy designed to stimulate immune cells such as natural killer (NK) cells and T cells.
Within bladder cancer, IBRX is advancing a randomized study evaluating Anktiva plus BCG in BCG-naïve NMIBC patients — a significantly larger population than the currently approved setting. The company is targeting a potential regulatory filing in the near term, with additional studies exploring the therapy across other disease settings that could further expand its addressable market.
Beyond bladder cancer, ImmunityBio is exploring Anktiva in combination with standard-of-care therapies and CAR-NK approaches across several difficult-to-treat cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma, colorectal cancer and hepatocellular carcinoma.
Successful development across the above -mentioned clinical studies could position Anktiva as a foundational immunotherapy platform for multiple cancer types, potentially supporting additional regulatory filings and long-term growth if clinical outcomes remain encouraging.
IBRX Faces Intense Competition in Target Markets
ImmunityBio faces stiff competition from Big Pharma in its target markets.
The company competes with well-established immunotherapies such as Merck’s (MRK - Free Report) Keytruda, Bristol Myers’ (BMY - Free Report) Opdivo and Roche’s (RHHBY - Free Report) Tecentriq. These drugs are already widely used across several oncology indications, including those targeted by IBRX.
Beyond having approved therapies, these pharma giants possess significantly greater financial resources, extensive global commercial infrastructure and well-established supply chains. Their long-standing presence in oncology gives them deep clinical development experience and strong relationships with physicians and treatment centers. This could make market penetration more challenging for newer entrants like ImmunityBio.
IBRX’s Price Performance, Valuation and Estimates
Shares of ImmunityBio have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, IBRX is trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 34.40 times forward 12-month sales, above the industry average of 1.99 times.
Image Source: Zacks Investment Research
Estimate movements for ImmunityBio’s 2026 and 2027 EPS have been mixed during the past 60 days.
View the Zacks #1 Rank List
Image: Bigstock
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
Key Takeaways
ImmunityBio’s (IBRX - Free Report) growth narrative is increasingly tied to the expansion potential of its sole marketed drug, Anktiva, beyond its initial approval in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). While the current label establishes a commercial foothold, the company is advancing multiple clinical programs aimed at extending the therapy’s use across broader oncology indications.
ImmunityBio is evaluating Anktiva in several clinical studies spanning solid tumors and hematologic malignancies as part of its broader Cancer BioShield platform strategy. Under this approach, the therapy acts as a backbone immunotherapy designed to stimulate immune cells such as natural killer (NK) cells and T cells.
Within bladder cancer, IBRX is advancing a randomized study evaluating Anktiva plus BCG in BCG-naïve NMIBC patients — a significantly larger population than the currently approved setting. The company is targeting a potential regulatory filing in the near term, with additional studies exploring the therapy across other disease settings that could further expand its addressable market.
Beyond bladder cancer, ImmunityBio is exploring Anktiva in combination with standard-of-care therapies and CAR-NK approaches across several difficult-to-treat cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma, colorectal cancer and hepatocellular carcinoma.
Successful development across the above -mentioned clinical studies could position Anktiva as a foundational immunotherapy platform for multiple cancer types, potentially supporting additional regulatory filings and long-term growth if clinical outcomes remain encouraging.
IBRX Faces Intense Competition in Target Markets
ImmunityBio faces stiff competition from Big Pharma in its target markets.
The company competes with well-established immunotherapies such as Merck’s (MRK - Free Report) Keytruda, Bristol Myers’ (BMY - Free Report) Opdivo and Roche’s (RHHBY - Free Report) Tecentriq. These drugs are already widely used across several oncology indications, including those targeted by IBRX.
Beyond having approved therapies, these pharma giants possess significantly greater financial resources, extensive global commercial infrastructure and well-established supply chains. Their long-standing presence in oncology gives them deep clinical development experience and strong relationships with physicians and treatment centers. This could make market penetration more challenging for newer entrants like ImmunityBio.
IBRX’s Price Performance, Valuation and Estimates
Shares of ImmunityBio have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, IBRX is trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 34.40 times forward 12-month sales, above the industry average of 1.99 times.
Image Source: Zacks Investment Research
Estimate movements for ImmunityBio’s 2026 and 2027 EPS have been mixed during the past 60 days.
Image Source: Zacks Investment Research
ImmunityBio currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.